The Pfizer Clinical Research Unit (PCRU) in Brussels is seeking healthy participants for a clinical trial of a study drug. 

This study will measure how much of the study drug is in your blood after you receive a single dose.

Who may participate

This study is seeking healthy male and female participants. Participants must be healthy, meaning they will not have the condition for which this treatment is being developed and are in overall good health. You may not take part in this study if:

  • You are younger than 18 years or you weigh less than or equal to 45 kg or you are outside of the limits for Body Mass Index (16 – 32 kg/m2)
  • For female participants: you are considered as capable of having children

There are other requirements for participation in this study. Please read attentively the Informed Consent Document (ICD), more explanation will be provided by the study staff during the screening process. 
 

Condition

Healthy

Age

18+

Sex

Male and non-childbearing potential female

Each clinical study has its own guidelines for who can participate, called eligibility criteria. However, only the research study staff can determine if you qualify to enroll in the study.

What to expect

If this study may be a fit for you, you’ll be invited to a screening visit at our facility in Brussels, Belgium.

You will stay in the PCRU for 2 treatment periods, each period comprised of 9 days and 8 nights in the PCRU, with a total duration of 18 days and 16 nights in the PCRU. The total duration of the study is 10 weeks.

You will be screened within 28 days prior to the first dose of study intervention.

Throughout the study, staff will closely monitor your health status and collect data.

You will not personally derive any benefit from your participation in this study, but the results obtained could be very important for the development of medicines and treatments which will benefit other people.
 

View calendar

How long is the study?

Approximately 10 weeks

Compensation

Up to € 4.600, plus travel fees